SCHEMBL2895563

SCHEMBL2895563

Cc1cc(-c2ccc(OC3CN(Cc4nc(C(C)C)no4)C3)cn2)ccc1C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.38
GPR183 P32249 1/20 0.38
S1PR1 P21453 10/20 0.35
S1PR5 Q9H228 2/20 0.35
S1PR4 O95977 1/20 0.35
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
S1PR3 Q99500 4/20 0.34
MAPT P10636 1/20 0.34
RARA P10276 1/20 0.33
RARB P10826 1/20 0.33
RARG P13631 1/20 0.33
PKM P14618 1/20 0.33
PIK3CG P48736 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2888289 0.93 GPR119 (0.38) GPR119GPR183S1PR1S1PR5S1PR4
SCHEMBL2894063 0.92 GPR119 (0.37) GPR119GPR183MAPT
SCHEMBL3663119 0.91 GPR119 (0.37) GPR119GPR183MAPT
SCHEMBL2887685 0.91 MAPT (0.38) GPR119GPR183MAPT
SCHEMBL13024281 0.91 GPR119 (0.39) GPR119GPR183S1PR1S1PR5S1PR4
SCHEMBL2893546 0.91 GPR119 (0.38) GPR119GPR183S1PR1S1PR5S1PR4
SCHEMBL2891413 0.90 GPR119 (0.37) GPR119GPR183
SCHEMBL2891418 0.90 GPR119 (0.38) GPR119GPR183MAPT
SCHEMBL13024332 0.90 GPR119 (0.36) GPR119GPR183MAPT
SCHEMBL2895880 0.89 GPR119 (0.35) GPR119GPR183MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286110-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2010-11-11 US disclosed
US-20100286110-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2010-11-11 US disclosed
US-20100286110-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2010-11-11 US disclosed
EP-2215078-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS Prosidion Limited (GB) 2010-08-11 EP disclosed
WO-2009050523-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 WO disclosed
WO-2009050523-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286110-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS GPR119, GIPR, GPR39 GPR119 1/4885GPR183 30/4885S1PR1 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.